J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gharaibeh, M.
Right arrow Articles by Waldman, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gharaibeh, M.
Right arrow Articles by Waldman, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers

MN Gharaibeh, LP Gillen, B Osborne, JI Schwartz, and SA Waldman

The erythromycin breath test (EBT), which measures 14CO2 produced from [14C N-methyl] erythromycin, is one of the most frequently employed measures to examine drug interactions involving cytochrome P450 3A4 (CYP3A). However, the reproducibility and reliability of this test, and the effects of drugs that alter CYP3A activity, continue to be defined. In this study, the reproducibility of the EBT was evaluated in eight healthy volunteers before and after oral administration of 600 mg of rifampin daily for 8 days. Two sequential EBT determinations performed 5 days apart before rifampin administration were highly reproducible. Rifampin induced CYP3A, reflected in a mean percent (+/- standard deviation) increase in EBT values of 86 +/- 30%. Recovery of enzyme function after discontinuation of rifampin for 17 days was manifested as a return of EBT values to preinduction levels. These results support the utility of EBT as a valid, reproducible, and reliable measure of CYP3A activity in vivo.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
P. J. Roberts, K. D. Rollins, A. D. M. Kashuba, M. F. Paine, A. C. Nelsen, E. E. Williams, C. Moran, J. K. Lamba, E. G. Schuetz, and R. L. Hawke
The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans
Drug Metab. Dispos., August 1, 2008; 36(8): 1465 - 1469.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
N. G. B. Agrawal, C. Z. Matthews, R. S. Mazenko, E. J. Woolf, A. G. Porras, X. Chen, J. L. Miller, N. Michiels, M. Wehling, A. Schultz, et al.
The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity
J. Clin. Pharmacol., October 1, 2004; 44(10): 1125 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. L. Veronese, L. P. Gillen, E. P. Dorval, W. W. Hauck, S. A. Waldman, and H. E. Greenberg
Effect of Mibefradil on CYP3A4 In Vivo
J. Clin. Pharmacol., October 1, 2003; 43(10): 1091 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. L. Veronese, L. P. Gillen, J. P. Burke, E. P. Dorval, W. W. Hauck, E. Pequignot, S. A. Waldman, and H. E. Greenberg
Exposure-Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice
J. Clin. Pharmacol., August 1, 2003; 43(8): 831 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. E. Polk, D. F. Brophy, D. S. Israel, R. Patron, B. M. Sadler, G. E. Chittick, W. T. Symonds, Y. Lou, D. Kristoff, and D. S. Stein
Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males
Antimicrob. Agents Chemother., February 1, 2001; 45(2): 502 - 508.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Clinical Pharmacology